Biotech Values

[y3maxx]

Biomaven,

""On November 2, 2007, the FDA acknowledged, in a letter to Amphastar from the Office of Generic Drugs, that Amphastar had met the FDA’s five “sameness” criteria and therefore had demonstrated its enoxaparin’s sameness with Lovenox® in its ANDA.""

Mouton,

""I checked the docket for the case and don't see an exhibit of said letter.""

Dew,

...If true, why is Amphastar proceding like this?

tia

y3